Loading...

PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GK1dot5_PE_021706
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 1_GK1dot5_PE_021706
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 2_GK15_PE_CD4_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (solid line) or rat IgG2b, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100407 50 µg $25
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100408 200 µg $72
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed
  2. Man SM et al. 2016. Cell. 167(2):382-396 . PubMed
  3. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  4. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  5. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  6. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  7. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  8. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  9. Friess MC, et al. 2022. Cell Rep. 38:110334. PubMed
  10. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  11. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  12. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  13. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  14. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  15. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  16. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  17. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  18. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  19. Willinger T, et al. 2014. J Exp Med. 211:685. PubMed
  20. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  21. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  22. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  23. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  24. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  25. Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed
  26. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  27. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  28. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  29. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  30. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  31. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  32. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  33. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  34. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  35. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  36. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  37. Yuan X, et al. 2019. JCI Insight. 4:e124317. PubMed
  38. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  39. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  40. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  41. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  42. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  43. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  44. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  45. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  46. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  47. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  48. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  49. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  50. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  51. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  52. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  53. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  54. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  55. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  56. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  57. Karki R, et al. 2020. JCI Insight. 5:00. PubMed
  58. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  59. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  60. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  61. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  62. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  63. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  64. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  65. Lv F, et al. 2022. iScience. 25:103639. PubMed
  66. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  67. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  68. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  69. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  70. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  71. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  72. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  73. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  74. Yang H, et al. 2022. Nutrients. 14:. PubMed
  75. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  76. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  77. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  78. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  79. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  80. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  81. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  82. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  83. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  84. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  85. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  86. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  87. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  88. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  89. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  90. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  92. Yang C, et al. 2013. Proc Natl Acad Sci U S A. 111:109. PubMed
  93. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  94. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  95. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  96. Du J, et al. 2018. AMB Express. 8:158. PubMed
  97. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  98. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  99. Cho K, et al. 2021. iScience. 24:103117. PubMed
  100. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  101. Colombo M, et al. 2022. iScience. 25:105042. PubMed
  102. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  103. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  104. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  105. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  106. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  107. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  108. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  109. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  110. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  111. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  112. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  113. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  114. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  115. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  116. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  117. Nakamura Y, et al. 2015. Infect Immun . 83:671. PubMed
  118. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  119. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  120. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  121. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  122. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  123. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  124. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  125. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  126. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  127. Zhang H, et al. 2009. Invest Ophthalmol Vis Sci. 50:2653. PubMed
  128. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  129. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  130. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  131. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  132. Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed
  133. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  134. Chen S, et al. 2022. iScience. 25:105176. PubMed
  135. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  136. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  137. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  138. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  139. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  140. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  141. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  142. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  143. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
  144. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  145. Mahlios J, Zhuang Y 2011. Mol Immunol. 49:227. PubMed
  146. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  147. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  148. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  149. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  150. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  151. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  152. Li H, et al. 2022. iScience. 25:104481. PubMed
  153. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  154. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  155. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  156. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  157. Gao P, et al. 2021. Nat Commun. 1194:12. PubMed
  158. Yomogida K, et al. 2013. Biochem Biophys Res Commun. 434:263. PubMed
  159. Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed
  160. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  161. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  162. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  163. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  164. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  165. Gawish R, et al. 2022. Elife. 11:. PubMed
  166. Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed
  167. Fu W, et al. 2020. J Immunol Res. 8820355:2020. PubMed
  168. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  169. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  170. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  171. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  172. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  173. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  174. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  175. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  176. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  177. Sun J, et al. 2012. Arterioscler Thromb Vasc Biol. 32:15:00. PubMed
RRID
AB_312692 (BioLegend Cat. No. 100407)
AB_312693 (BioLegend Cat. No. 100408)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account